A New Mixed-Backbone Oligonucleotide against Glucosylceramide Synthase Sensitizes Multidrug-Resistant Tumors to Apoptosis

Gauri A. Patwardhan, Qian-Jin Zhang, Dongmei Yin et al. · 2009

Read A New Mixed-Backbone Oligonucleotide against Glucosylceramide Synthase Sensitizes Multidrug-Resistant Tumors to Apoptosis by Gauri A. Patwardhan, Qian-Jin Zhang, Dongmei Yin et al. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0006938.txt.

Description

Gauri Patwardhan, Qian-Jin Zhang, Dongmei Yin, and colleagues tested a new cancer drug aid in PLOS ONE in 2009. Many tumors resist chemotherapy, and an enzyme called glucosylceramide synthase helps them do it. The enzyme boosts a process that limits drugs such as doxorubicin. The team built a mixed-backbone oligonucleotide aimed at that enzyme.

Their short synthetic strand was designed to lower the enzyme's activity. They tested it on multidrug-resistant tumors. The treatment made resistant cells more likely to die by apoptosis. Blocking this enzyme could restore the power of standard cancer drugs in tumors that no longer respond.

Catalog record

CREATORGauri A. Patwardhan, Qian-Jin Zhang, Dongmei Yin et al.
YEAR2009
COLLECTIONPAPERS
FORMATTXT
FILE SIZE47 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0006938

Browse the full library · About the Tower of Babel